-+ 0.00%
-+ 0.00%
-+ 0.00%

OliX Pharma New Zealand Phase 2a trial application for OLX10212 rejected by ethics committee

PUBT·10/12/2026 07:07:04
OliX Pharma New Zealand Phase 2a trial application for OLX10212 rejected by ethics committee
  • OliX Pharmaceuticals’ New Zealand IND application for OLX10212 in geographic atrophy linked to age-related macular degeneration was rejected.
  • Northern B Health and Disability Ethics Committee cited non-compliance with local ethical standards or relevant laws.
  • Rejection notice received on Oct. 12, 2026, delaying a planned Phase 2a trial using intravitreal injections.
  • Company preparing a resubmission following review of the committee’s findings.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OliX Pharmaceuticals Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261012900388), on October 12, 2026, and is solely responsible for the information contained therein.